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ABSTRACT 
Funding policy and a medico-legal climate are part of physicians’ reality and might permeate 
clinical decisions. This study evaluates the influence of maternal age and government funding on 
obstetrician/gynecologist recommendation for invasive prenatal testing (i.e. amniocentesis) for 
Down syndrome (DS), and its association with the physician’s assessment of the risk of liability 
for medical malpractice unless they recommend amniocentesis. 
Israeli physicians (N=171) completed a questionnaire and provided amniocentesis 
recommendations for women at 18 weeks gestation with normal preliminary screening results, 
identical except aged 28 and 37.   
Amniocentesis recommendations were reversed for the younger (‘yes’ regardless of testing 
results: 6.4%; ‘no’ regardless of testing results: 31.6%) versus older woman (‘yes’ regardless of 
testing results: 40.9%; ‘no’ regardless of testing results: 7.0%; χ²=71.55, p<.01). About half of 
the physicians endorsed different recommendations per scenario; of these, 65.6% recommended 
amniocentesis regardless of testing results for the 37-year-old woman. Physicians routinely 
performing amniocentesis and those advocating for amniocentesis for all women ≥ age 35 were 
approximately twice as likely to vary their recommendations per scenario. Physicians who 
perceived risk of liability for malpractice as large were nearly one-and-a-half times more likely 
to vary recommendations.  
The results indicate physicians' recommendations are influenced by maternal age, though age is 
already incorporated in prenatal DS risk evaluations. The physician’s assessment of the risk that 
they will be sued unless they recommend amniocentesis may contribute to this spurious 
influence. 
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Studies have shown that physicians incorporate background factors that may exert a subjective 
influence on clinical decision making, when deciding whether to administer amniocentesis 
testing (Asher et al. 2013; Jena et al. 2015; Srebnik et al. 2013). Here, we examined the effect of 
legal concerns on physicians’ recommendations for invasive prenatal diagnostic testing for 
Down syndrome, beyond the effect of the clinical information, i.e. screening results. This is an 
example when a medico-legal climate, and the way the public interprets funding practices, may 
permeate recommendations. 
Since 1993 the Israeli Ministry of Health has funded amniocentesis for all women of 
advanced maternal age (‘AMA’), i.e., of 35 years of age or older. Likewise, it has funded 
amniocentesis for women younger than 35 years based on high risk ultrasound findings or 
relevant family history (Israel Ministry of Health 1992; Israel Ministry of Health 2007; Israel 
Ministry of Health 2011; Israel Ministry of Health 2013). This has led to a prevailing belief 
among Israeli women that age is a risk factor in and of itself and that AMA women must have 
amniocentesis (Grinshpun-Cohen et al. 2014; Grinshpun-Cohen et al. 2015). Indeed, a study 
among Israeli women with normal triple serum screening results found that 87.6% of AMA 
women had amniocentesis, while only 6.6% of younger women had the procedure (Grinshpun-
Cohen et al. 2015). The reasoning often referred to age as necessitating amniocentesis. 
This belief is not medically supported by the American College of Obstetricians and 
Gynecologists (ACOG) guidelines, which stated in 2007 that neither 35 years nor any specific 
age should be used as a threshold for invasive or non-invasive testing.  Notably, the Israeli 
funding policy does not mandate amniocentesis for AMA women, but rather states that they are 
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eligible for funding, and that recommendations should be based on screening results (Israeli 
Ministry of Health n.d.). 
The mismatch between beliefs and funding guidelines is not the only complicating factor. 
Complication is compounded for physicians by a medico-legal climate; evidence suggests that 
physicians' decisions are influenced by fear of being liable for malpractice (Shwayder 2010; 
Socol and Socol 2012). For example, a study on cesarean sections concluded that the liability 
environment influences the choice of delivery method in obstetrics and that fear of liability is a 
strong motivator in physicians' decision to offer testing (e.g., for cystic fibrosis) (Morgan et al. 
2004; Pergament and Ilijic 2014; Stark et al. 2013). Indeed, to mitigate perceived liability, 
obstetricians and gynecologists may seek out laboratories that test for as many fetal genetic 
mutations as possible (Kaufman et al. 2008).  
In order to examine whether physicians' recommendations about invasive prenatal 
diagnostic testing are influenced by legal concerns, an issue that is increasingly relevant, the 
present study compares recommendations made by Israeli physicians for a 28-year-old woman 




Prior to data collection, an exemption for ethical approval was obtained from the institutional 
review board committee of Shaare Zedek Medical Center as this is a non-interventional, 
observational study that does not involve direct contact with patients or patient identifying 
information. A link to an anonymous online questionnaire was emailed to the directors of the 
four regional branches of the Israeli Society for Obstetrics and Gynecology and to the chairs of 
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obstetrics and gynecology departments at Israeli hospitals asking that they distribute the link to 
all their staff members. Both in the email and on the first screen of the survey website, the study 
was presented as a 'position survey on maternal age and amniocentesis'.  
Settings 
The data were collected in 2011-2012. We state this, because non-invasive cell free fetal DNA 
prenatal testing (NIPT) (ACOG 2015; Buchanan et al.2014), which is increasingly becoming an 
acceptable alternative to amniocentesis, was not yet widely used, and therefore, its presence did 
not emerge in physician responses to the survey, nor could it have been included.  
In Israel, most pregnant women visit public clinics fully covered by the national health insurance 
system. The follow up is conducted by a general OB/GYN every 4-6 weeks. Ultrasound 
examinations, including mid trimester anatomic scan, and second trimester 'triple test' are fully 
covered. In addition, the vast majority of the young Israeli population holds complementary 
health insurance, covering nuchal translucency and first trimester serum screening tests, (which 
became part of the national health insurance policy in 2012), and most costs of amniocentesis, as 
indicated.  Therefore, monetary cost is usually not a significant personal issue. Either the 
OB/GYN the woman usually sees or another clinician performs the amniocentesis through a 
public or private service.  
Procedures 
Participants provided informed consent and were then presented with a clinical scenario 
as part of a larger study on views concerning invasive prenatal diagnostic testing (Srebnik et al. 
2013). Here we report on data relevant to physicians' recommendations regarding the same 
scenario at two different maternal ages. The scenario described the case of a pregnant woman at 
18 weeks gestation who came in to discuss results of biochemical and sonographic screening 
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results, pointing to low risk for Down syndrome (defined as 1:380 or lower by the Israeli 
Ministry of Health). The scenario stated that all risks and benefits of performing or avoiding 
amniocentesis were discussed with the patient. Participants received two versions of the scenario 
in random order, one referring to a 28-year-old pregnant woman and the other referring to a 37-
year old pregnant woman. The versions were otherwise identical. 
Participants were asked to read each woman’s scenario and indicate their 
recommendation by selecting one of five options: 
(i) I would recommend performing amniocentesis. 
(ii) I would recommend performing amniocentesis if the risk according to screening 
results is high in my opinion. 
(iii) I would recommend avoiding amniocentesis. 
(iv) I would refuse to state my opinion. 
(v) None of the above reflects my opinion. 
After choosing an option, participants responded to several demographic questions (age, 
gender, years of experience, whether they perform amniocentesis and place of work). 
Next, participants were asked to rank their agreement with statements about amniocentesis. 
Data Analysis 
First, we measured the correlation between all variables in the dataset.  Next, we created 
a variable categorizing physicians into those who gave different recommendations for the 28-
year-old scenario and the 37-year-old scenario, and those that gave the same recommendation. 
For example, if the clinician recommended avoiding amniocentesis for the 28-year-old scenario 
but recommended amniocentesis regardless of testing results for the 37-year-old scenario, the 
clinician would be categorized as one whose recommendations differed. Then, we conducted a 
  9 
 
binary logistic regression to examine the influence of demographic characteristics and attitudes 
towards amniocentesis on the physicians' recommendation in the two different age scenarios. 
A sign test (Dixon and Mood 1946) was conducted for the physicians who varied their 
recommendations per scenario in order to examine if physicians' recommendations became more 
aggressive for the scenario of the AMA woman. To perform the sign test, we first removed the 
21 physicians who responded with ‘none of the above’ for only one scenario, as to be able to 
scale the remaining responses (‘no’, ‘depends on screening result’, and ‘yes’) ordinally.  
The study did not have any external funding source. 
 
RESULTS 
A total of 188 physicians completed the questionnaire. Seventeen participants were 
excluded due to refusal to state their recommendations regarding the described scenarios. The 
analysis was therefore based on 171 participants. Demographic characteristics are shown in 
Table I.  
Figure 1 shows the proportion of physicians who endorsed each recommendation for the 
two scenarios (28-year-old, 37-year-old). Prevalence of recommendations favoring 
amniocentesis was only 6.4% for the 28-year-old woman, but 40.9% for the 37-year-old woman. 
Conversely, prevalence of recommendations to avoid amniocentesis was 31.6% for the 28-year-
old woman, but only 7.0% for the 37-year-old woman. Of the 171 physicians included in the 
study, 81 had the same recommendation for both, while 90 varied their recommendations 
between the 28-year-old woman and the 37-year-old woman. As hypothesized, the sign test 
revealed that physicians were more likely to recommend more aggressive testing for the 37-year-
old woman than the 28-year-old woman, z = -8.066, p < 0.001.  (There were only 15 physicians 
who changed their recommendation from ‘no’ for the younger woman to ‘yes’ for the older 
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woman. A binomial test performed on the smaller number, 0, revealed that there was a 0.0031% 
chance of having 0 ‘successes’ out of 15.)      
Table II shows the percentage of physicians’ responses to various statements regarding 
their attitudes toward amniocentesis. The table indicates that the majority of physicians agreed 
with the argument that failing to recommend amniocentesis for women over the age of 35 may 
result in liability in a medical malpractice lawsuit if a baby is born with Down syndrome 
(‘Highly agree’ and ‘Agree’: n = 114, 67.1%). In contrast, over half of the physicians (56.8%) 
disagreed with the argument that over the age of 35, the risk of missing the Down syndrome 
diagnosis in a fetus during preliminary screening is too high, and it is therefore justified to 
perform amniocentesis in all pregnancies (‘Completely disagree’ and ‘Disagree’; n = 96, 56.8%).  
Nearly half of the physicians disagreed with the argument that no referral for amniocentesis over 
the age of 35 years is interpreted by the patient as inappropriate and unprofessional medical 
procedure (‘Completely disagree’ and ‘Disagree’; n = 79, 46.5%).   
The representation of the physicians’ recommendations at maternal age of 37 years 
relative to those at age 28 years allowed us to distinguish among physicians who endorsed the 
same recommendations and those that endorsed different recommendations at the two maternal 
ages (28 and 37; Figure 2). Overall, about half the physicians endorsed different 
recommendations (n=90 of 171, 52.6%). Of the physicians who endorsed different 
recommendations, the majority (n = 59, 65.6%) did not favor automatic amniocentesis for the 
younger woman but favored amniocentesis regardless of screening results in the older woman 
(Figure 2b), and only 21.1% of these said they would recommend amniocentesis based on the 
risk associated with the screening results, even though the experimental scenario stated that these 
results were normal. 
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The statement, “Over the age of 35, the risk of missing the DS diagnosis in a fetus is too 
high and therefore it is justified to perform amnio in all pregnancies” was found to be negatively 
correlated with recommending amniocentesis to the 37-year-old woman, -.488, p < 0.001.  (The 
negative correlation is due to a decision to code the statements of greater agreement as higher 
values, whereas the recommendations for amnio were coded as 1 for ‘yes’, 2 for ‘depends’, 3 for 
‘no’, etc.) 
Next, backward stepwise binary logistic regression analysis was conducted to examine 
which predictors were associated with physicians' endorsement of different (vs. the same) 
recommendation depending upon the maternal age (28 and 37 years) of the woman in the 
scenario. Predictors included clinician demographic characteristics (i.e., years of experience, 
gender and whether they perform amniocentesis) as well as their attitudes toward amniocentesis.  
This analysis revealed that the more the clinician agreed with the statement that over age 35, the 
high risk of missing Down syndrome during preliminary screening justifies performing 
amniocentesis in all pregnancies, the more likely s/he was to make a different recommendation 
for a 37-year-old woman as compared to a 28-year-old woman (odds ratio OR: 1.92; 95% 
CI:1.42 –2.58). Likewise, degree of agreement with the statement that not recommending 
amniocentesis for women over the age of 35 would risk liability in a malpractice suit if a Down 
syndrome baby were born was associated with a higher likelihood of a different recommendation 
at maternal age 37 vs. 28 (OR: 1.47; 95% CI: 1.12–2.58). The variation in degree of agreement 
with these statements among physicians with either the same or differing recommendations per 
scenario is illustrated in Figure 3. Similarly, physicians with fewer years of experience (OR: 
1.04; 95% CI: 1.00–1.08) and those who routinely perform amniocentesis (OR: 2.19; 95% CI: 
1.03–4.63) were more likely to make a different recommendation for the 37-year-old woman. 
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Gender, age, place of work, and the agreement with the statement about patient interpretation of 
lack of amniocentesis recommendation were all non-significant predictors and were thus 
excluded from the final model. Figure 4 shows the ROC curves for the (A) original and (B) final 
models.  Table III is the final regression table for our model.  
 
DISCUSSION 
Clinical judgment as a whole, but especially regarding procedures and invasive diagnostic 
testing, requires knowledge, skill, and responsibility. The clinical environment is increasingly 
complex, and a growing body of evidence shows that clinical decision making nowadays is also 
impacted by concerns over malpractice suits (ACOG 2013), which may lead to defensive 
medicine (Asher et al. 2013), and by funding policies and the way the public interprets them as 
informing what should be done, rather than what could be done, with health insurance funding 
(Shurtz et al. 2016). To our knowledge, the present study is the first to extend this line of 
investigation to examining whether physicians' recommendations for invasive prenatal diagnostic 
testing can be influenced by non-clinical factors such as maternal age, and legal concerns.   
Our data show that physicians' decisions are swayed by the age of the expectant mother 
in the absence of clinical justification. That is, age is already accounted for as triple serum 
screening results are calculated as a function of the presence of biochemical markers, as well as 
maternal age. Therefore, there is no need to factor in age again to the mental calculation of risk. 
Thus, when the physicians in our study considered maternal age separately from the screening 
results, they were effectively placing additional weight on age alone and either placing lower 
weight on the screening results or dismissing them altogether (in the case of normal screening 
results). Indeed, a significant portion of respondents exhibited precisely this tendency, by 
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recommending amniocentesis to an AMA woman whose clinical profile was identical to that of a 
younger woman for whom they did not recommend invasive diagnostic testing.  
There was a close split among the participants: 52.6% of the respondents made a different 
prenatal testing recommendation for the younger woman vs. the older one, while 47.4% retained 
the same recommendation. The most common difference was between recommending 
amniocentesis to a 28-year-old woman depending upon the screening result, but recommending 
amniocentesis to a 37-year-old without any dependence on previous screening results. The main 
measure that correlated with physicians' decision to recommend amniocentesis at 35 was their 
degree of agreement with the statement: "Over the age of 35, the risk of not diagnosing Down 
syndrome following preliminary screening of a fetus is too high, and therefore it is justified to 
perform amniocentesis in all pregnancies.” However, clinical data show that the detection rate 
for women over 35 years of age during preliminary prenatal screening is higher compared to the 
detection rate for their younger counterparts (89.8% of DS pregnancies vs. 66.7% of DS 
pregnancies) (Simpson 2012). It might be that there is a prevailing belief among physicians that 
they are expected to prescribe amniocentesis at AMA due to government funding, and that this is 
being interpreted as having a medical basis. 
As previously mentioned, the main measure that correlated with physicians' decision to 
recommend amniocentesis at 35 was their degree of agreement with the (untrue) statement: 
"Over the age of 35, the risk of not diagnosing Down syndrome following preliminary screening 
of a fetus is too high, and therefore it is justified to perform amniocentesis in all pregnancies.” 
We attribute the increased weight these OB/GYNs placed on maternal age to two factors, the 
first being physicians’ limited understanding of screening test statistics (Wegwarth et al. 2012). 
Research has shown that OB/GYNs have gaps in their ability to comprehend statistical concepts 
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(Anderson et al. 2014), and, perhaps surprisingly, genetic counselors often need further 
clarification from the testing laboratory about test results (McGovern et al. 2003).  If this is true 
of genetic counselors with thorough genetics training, it is certainly reasonable to assume that 
OB/GYNs with minimal genetics training should feel less than confident in their knowledge and 
interpretation of results. The second factor for the association between age and risk is that in 
Israel where the study took place, public funding exists for amniocentesis after the age of 35. 
This, in and of itself, creates a climate associating this age as one in which amniocentesis is 
required, at least as perceived by patients (Grinshpun-Cohen et al. 2014; Grinshpun-Cohen et al. 
2015).  The two factors may compound. In the absence of thorough understanding of the 
screening test, physicians may make the leap from public funding guidelines to age-associated 
risk. This would result in the prevalent, yet false, belief that was present in our sample that the 
high risk of not diagnosing DS during preliminary screening at AMA justifies performing 
amniocentesis in all AMA pregnancies. 
 
Option (ii), “I would recommend performing amniocentesis if the risk according to 
screening results is high in my opinion”, was designed to give physicians room to interpret the 
screening results as they see fit.  It effectively created an ordinal scale of ‘no’, ‘depends’, and 
‘yes’.  The fact that so many physicians chose this option indicates that they take the threshold 
recommended by the Israeli Health Ministry with a grain of salt, factoring in other elements.  
Although, we cannot say exactly what those elements are. Figure 2 shows that more physicians 
varied their answers depending on age (90 physicians) than physicians who responded identically 
for both age scenarios (81 physicians).  Furthermore, Figure 2B shows that a clear majority of 
the physicians who varied their recommendations ‘upgraded’ their recommendation to be more 
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aggressive when moving from the 28-year-old woman to the 37-year-old woman; that is, either 
from ‘depends on screening test’ to ‘yes’, ‘no’ to ‘yes’, or ‘no’ to ‘depends on screening test’.  
Practice Implications 
While we tested amniocentesis recommendations in Israel, the topic examined in this 
study is much broader, and spans other countries and other instances, where availability of 
funding is perceived as a directive to screen, test (Zhao et al. 2013), vaccinate (Hayashi et al.  
2012), etc. In Israel, as in the UK, (National Health Service, UK 2014), amniocentesis is fully 
funded above the age of 35, which women take as an indication that the test is mandatory or at 
least highly recommended; AMA women who know that their screening results are normal 
choose nonetheless to undergo amniocentesis and cite their age as a determining factor 
(Grinshpun-Cohen et al. 2015). Therefore, for a clinician to recommend against the test to an 
AMA woman is a non-trivial and potentially controversial decision (Blumenthal-Barby and 
Krieger 2014; Croskerry 2015).  
The second important factor influencing whether physicians made a different 
recommendation for a younger vs. older woman was concern over liability in potential litigation 
if they did not recommend amniocentesis. The physician’s assessment of the risk of a lawsuit 
unless they recommend amniocentesis has previously been demonstrated to play a role in 
physicians' decisions. Bishop and colleagues (Bishop et al. 2010) found that physicians consider 
malpractice fear as a problem impacting their practice. In the field of obstetrics, for example, it 
has been shown that litigation fear directly contributes to the rising prevalence of cesarean 
sections (Minkoff 2012; Rossignol et al. 2013).  
Study Limitations 
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This study has several limitations, including a relatively modest sample size and number 
of predictor variables. Secondly, we were unable to ascertain the true representativeness of our 
sample.  The survey was broadly distributed, potentially reaching all obstetrician/gynecologists 
and OB/GYN residents in Israel (1200; Shen et al. 2010), but was completed by only 14% of 
them (or 16% of the1000 obstetrician/gynecologists, as residents were ultimately excluded from 
analysis). However, in the absence of data on how many failed to receive the email link to the 
survey, we cannot report a true response rate. Still, because confounding factors like age, gender 
and clinical settings (hospital versus community) did not affect the results, a selection bias for 
respondent answers appears to be unlikely. Further, our sampling rate is higher than the 7% of 
Israeli physicians sampled in a recent national survey (Asher et al. 2012) and comparable with 
those of other surveys of the membership of large medical associations (Raffi et al. 2012; 
Ghaderi et al. 2013).  Thirdly, the study was conducted in Israel, and cultural factors may limit 
its generalizability. Still, Israel, like the US, endorses guidelines defining AMA as a possible 
indication for amniocentesis testing, and the guideline is therefore relevant to physicians' 
choices. A fourth limitation is that physicians were asked to provide recommendations based 
upon hypothetical scenarios rather than actual clinical scenarios. However, this aspect of the 
study design may also be considered a strength in that these decisions were inherently 
independent of patient preferences, which are influenced by a plethora of reasons (Lesser and 
Rabinowitz 2001). This provides unique insight into physicians' preferences, motivations, and 
potential concerns. Additionally, as this survey was circulated only among OB/GYN physicians 
and not genetic counselors, for example, there was no way to compare physician and genetic 
counselor attitudes towards amniocentesis. Finally, invasive prenatal testing may quickly be 
supplanted by newer, non-invasive techniques, which, when applied contingently, are also cost-
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effective (Gyselaers et al. 2015). More specifically, another issue that this study does not address 
is the addition of NIPT as an important option to physicians' arsenal of non-invasive screening 
tests (Gyselaers et al. 2015). However, the issue of the influence of non-clinical factors on 
clinical decisions remains highly relevant. NIPT notwithstanding, the dilemma at the core of this 
study of noninvasive screening vs. invasive diagnostic testing has not been resolved. In fact, this 
dilemma has become even more complex, given the added options with overlapping but not 
identical benefits (Pergament & Ilijic 2014).  NIPT offers genetic information through a simple 
blood test, while amniocentesis is an invasive procedure, which carries risk. However, the 
accuracy of NIPT is believed to be better in the high-risk population, compared to the general 
obstetric population. Therefore, the American College of Obstetricians & Gynecologists 
recommend that it not be used as the sole consideration in pregnancy management decisions 
(ACOG 2015).   
Research Recommendations 
Our results suggest that OB/GYN physicians' choices regarding prenatal diagnosis are 
influenced by the medico-legal climate and might demonstrate the practice of defensive 
medicine. The results demonstrate a higher prevalence of amniocentesis recommendations for an 
AMA woman, whereas a younger woman presenting with the same screening results would 
receive a different recommendation.  While maternal age is an integral part of screening results 
for Down syndrome, a significant portion of doctors who would recommend avoiding an 
invasive prenatal diagnostic test at younger maternal age would recommend such testing at 
advanced maternal age, even when screening results are low. Fear of legal liability may 
contribute to this tendency, which indicates that the reasons for the different recommendations 
are not purely medical. This can be taken one step further by examining other funding and 
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reimbursement policies and their effect on physicians' recommendations, as well as on patients’ 
reading of the situation. Such a line of work can inform the allocation of financial resources, and 
the way policies are designed and implemented to address the medico-legal challenges which 
physicians face. This may help address the recent call to optimize women's healthcare resources 
(Jennings 2014), including the decrease in unnecessary tests.  
Additionally, prenatal genetic counseling may be provided by a geneticist (physician), a 
genetic counselor, or OB/GYN provider (Israel Ministry of Health 2017; Sagi and Uhlmann 
2013).  This study only investigated OB/GYN physicians’ attitudes towards invasive procedures 
in Israel.  However, the dilemmas presented to respondents here are commonly relevant to other 
professionals who provide prenatal genetic counseling.  Future research can investigate how 
physicians from other medical specialties and how other clinicians within in the field of 
OB/GYN view invasive diagnostic tests and procedures.  
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